Jaana E Martikainen

Summary

Affiliation: Social Insurance Institution
Country: Finland

Publications

  1. ncbi request reprint Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 29:2468-76. 2007
  2. ncbi request reprint European prices of newly launched reimbursable pharmaceuticals--a pilot study
    Jaana Martikainen
    Research Department, The Social Insurance Institution, P O Box 450, FIN 00101 Helsinki, Finland
    Health Policy 74:235-46. 2005
  3. doi request reprint New chemical entities and their market penetration in Finland during the years 1996 through 2005
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 31:668-76. 2009
  4. doi request reprint Impact of restricted reimbursement on the use of statins in Finland: a register-based study
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Med Care 48:761-6. 2010
  5. pmc The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland
    Hanna Koskinen
    Research Department, The Social Insurance Institution, P O Box 450, 00101, Helsinki, Finland
    Health Econ Rev 4:9. 2014
  6. doi request reprint Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland
    Hanna Koskinen
    The Social Insurance Institution, Research Department, Helsinki, Finland Electronic address
    Value Health 18:1105-12. 2015
  7. doi request reprint Cost-related barriers to use of health services and prescription medicines in Finland: a cross-sectional survey
    Katri Aaltonen
    1 The Social Insurance Institution, Research Department, Helsinki, Finland
    Eur J Public Health 25:368-72. 2015
  8. doi request reprint Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005
    Hanna Koskinen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 31:1469-77. 2009
  9. ncbi request reprint At-risk patients still predisposed for myocardial infarction by coxibs
    Arja Helin-Salmivaara
    Eur J Clin Pharmacol 63:97-8. 2007

Detail Information

Publications9

  1. ncbi request reprint Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 29:2468-76. 2007
    ..In Finland, new antiglaucoma drugs start with a high copayment, but once sufficient clinical experience is available, they are reevaluated and can receive a lower copayment status...
  2. ncbi request reprint European prices of newly launched reimbursable pharmaceuticals--a pilot study
    Jaana Martikainen
    Research Department, The Social Insurance Institution, P O Box 450, FIN 00101 Helsinki, Finland
    Health Policy 74:235-46. 2005
    ..Wholesale prices were highest in those countries where manufacturers are free to set the prices of their products. Pharmacy margins and taxes, however, change the ranking of the most expensive or the cheapest countries...
  3. doi request reprint New chemical entities and their market penetration in Finland during the years 1996 through 2005
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 31:668-76. 2009
    ..There is little empirical information about the role of new chemical entities (NCEs) and to what extent they are being adopted in modern health care...
  4. doi request reprint Impact of restricted reimbursement on the use of statins in Finland: a register-based study
    Jaana E Martikainen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Med Care 48:761-6. 2010
    ..This study investigated the short-term consequences of the restricted reimbursement of expensive statins (atorvastatin and rosuvastatin) on the use of statins in Finland...
  5. pmc The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland
    Hanna Koskinen
    Research Department, The Social Insurance Institution, P O Box 450, 00101, Helsinki, Finland
    Health Econ Rev 4:9. 2014
    ..Furthermore, the additional impact of reference pricing on prior implemented generic substitution is assessed...
  6. doi request reprint Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland
    Hanna Koskinen
    The Social Insurance Institution, Research Department, Helsinki, Finland Electronic address
    Value Health 18:1105-12. 2015
    ..The additional impact of reference pricing over and above previously implemented generic substitution was also assessed...
  7. doi request reprint Cost-related barriers to use of health services and prescription medicines in Finland: a cross-sectional survey
    Katri Aaltonen
    1 The Social Insurance Institution, Research Department, Helsinki, Finland
    Eur J Public Health 25:368-72. 2015
    ..The objective was to examine cost-related barriers to using health services and prescription medicines in Finland...
  8. doi request reprint Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005
    Hanna Koskinen
    Research Department, The Social Insurance Institution, Helsinki, Finland
    Clin Ther 31:1469-77. 2009
    ..Antipsychotics and antidepressants are among the fastest-growing therapeutic classes, but the reasons behind recent cost growth are not clear...
  9. ncbi request reprint At-risk patients still predisposed for myocardial infarction by coxibs
    Arja Helin-Salmivaara
    Eur J Clin Pharmacol 63:97-8. 2007